Menu

Category: Federal

J&J, Lilly and GSK to Refund 340B Covered Entities for Overcharges

Shannon Young, Associate Editor/Senior Writer Views
Johnson & Johnson and two other major drugmakers recently announced refunds for 340B covered entities that purchased certain drugs in 2022 and 2023.
Three major drugmakers recently announced refunds for 340B covered entities that purchased certain drugs in 2022 and 2023 following recalculations [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Cassidy Staffer, ASAP 340B Head Call for 340B Program Reforms, Comment on Proposed Shift to CMS

Shannon Young, Associate Editor/Senior Writer Views
Jeffrey Last, U.S. Sen. Bill Cassidy’s (R-La.) legislative lead on 340B, highlighted the findings and recommendations of the HELP Committee chairman’s late-April report on the 340B program at a June 4 webinar.
A key health policy staffer for U.S. Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Bill Cassidy (R-La.) recently [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Sandoz to Stop Notifying CEs of 340B Contract Pharmacy Changes, Joins Liquidia in Adding Restrictions to New Drugs; Novartis Updates Restrictions

Shannon Young, Associate Editor/Senior Writer Views
Sandoz announced in a June 4 notice to covered entities it “will no longer be providing additional notification for product changes to [its] contract pharmacy policy.”
Two drugmakers recently added new medications to the list of drugs subject to their respective 340B contract pharmacy restrictions—one of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

In Emergency Motion, Novartis and BMS Urge Appellate Court to Fast-Track Their Appeals of 340B Rebate Ruling

William Newton, Associate Editor/Senior Writer Views
Novartis and BMS filed an emergency motion with the federal appeals court in Washington, D.C. to appeal a recent ruling on drugmaker 340B rebates.
Novartis and Bristol Myers Squibb (BMS) are asking a federal appeals court to expedite their challenge to a recent ruling [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Premier Asks Court to Reject HRSA’s Defense of 340B Hospital Drug Purchasing Restrictions Policy, Requests Oral Arguments

Shannon Young, Associate Editor/Senior Writer Views
Premier again asked a Washington D.C. federal court to strike down a HRSA policy that restricts how certain 340B hospitals can purchase initial drug inventory.
A major group purchasing organization (GPO) recently urged a Washington D.C. federal court to reject the federal government’s defense of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

State Contract Pharmacy Lawsuit Roundup: Drugmakers File Briefs in 5th Circuit Appeals Case, Updates in Utah and Nebraska

Shannon Young, Associate Editor/Senior Writer Views
Key briefs were filed in litigation on contract pharmacy access laws in Louisiana, Utah and Nebraska.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

340B Stakeholders Offer Mixed Views on Trump’s Plan to Move Drug Pricing Program to CMS

Shannon Young, Associate Editor/Senior Writer Views
340B advocates and stakeholders offered mixed reactions to President Donald Trump's HHS budget request, which called for moving the 340B program to CMS.
340B stakeholders and attorneys offered mixed initial reactions this week to President Donald Trump’s proposal to move the 340B program [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Breaking News

Trump’s Full 2026 Budget Request Would Shift 340B Program from HRSA to CMS, Maintain Current OPA Funding

William Newton, Associate Editor/Senior Writer Views
CMS would assume oversight of the 340B program under the White House’s full fiscal year 2026 budget proposal released May 30.
President Donald Trump’s fiscal year 2026 budget request released yesterday calls for moving control of the 340B program away from [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

First 340B Administrative Dispute Resolution Panel Decision Sides with Drug Industry

William Newton, Associate Editor/Senior Writer Views
The first decision was recently issued under HRSA's revised 340B Administrative Dispute Resolution process.
The first published decision under the revamped 340B Administrative Dispute Resolution (ADR) process sided with the drug industry, marking a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Katie Miller, Key Player in Anti-340B ‘Dark Money’ Campaign, Leaves White House Adviser Role

Shannon Young, Associate Editor/Senior Writer Views
Katie Miller, a key figure in a dark money anti-340B campaign, has left her role as a White House adviser.
A Trump administration adviser and key figure in a dark money effort to tie the 340B program to immigration growth, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live